Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology

[1]  M. Fujimoto,et al.  Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosis–Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement , 2014, Arthritis care & research.

[2]  A. Hashimoto,et al.  Predictors of Survival and Causes of Death in Japanese Patients with Systemic Sclerosis , 2011, The Journal of Rheumatology.

[3]  M. Sharma,et al.  Detection of the membrane attack complex as a diagnostic tool in dermatomyositis , 2011, Acta neurologica Scandinavica.

[4]  L. Mouthon,et al.  Myopathies related to systemic sclerosis: a case–control study of associated clinical and immunological features , 2010, Scandinavian journal of rheumatology.

[5]  A. Pestronk,et al.  Mitochondrial pathology in immune and inflammatory myopathies , 2010, Current opinion in rheumatology.

[6]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[7]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[8]  T. Medsger,et al.  Anti-U3 RNP autoantibodies in systemic sclerosis. , 2009, Arthritis and rheumatism.

[9]  L. Mouthon,et al.  A descriptive and prognostic study of systemic sclerosis-associated myopathies , 2008, Annals of the rheumatic diseases.

[10]  B. Engelen,et al.  The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and Polyneuropathies): Development and preliminary data , 2007, Neuromuscular Disorders.

[11]  M. Dalakas,et al.  Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies , 2006, Nature Clinical Practice Neurology.

[12]  M. Jinnin,et al.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy , 2005, Clinical Rheumatology.

[13]  R. Hughes,et al.  119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[14]  G. Borm,et al.  Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. , 2004, Journal of neurology, neurosurgery, and psychiatry.

[15]  K. Takehara.  Hypothesis: pathogenesis of systemic sclerosis. , 2003, The Journal of rheumatology.

[16]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[17]  T. Medsger,et al.  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. , 1993, American heart journal.

[18]  M. Trucco,et al.  Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.

[19]  T. Mimori.  Scleroderma‐Polymyositis Overlap Syndrome , 1987 .

[20]  J. Mendell,et al.  Microvascular deposition of complement membrane attack complex in dermatomyositis. , 1986, The New England journal of medicine.

[21]  T. Mimori,et al.  Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. , 1981, The Journal of clinical investigation.

[22]  S. West,et al.  Association of myositis and myocarditis in progressive systemic sclerosis. , 1981, Arthritis and rheumatism.

[23]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[24]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[25]  H. Paulus,et al.  Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. , 1978, Arthritis and rheumatism.

[26]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[27]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .

[28]  A. Masi,et al.  Epidemiology of systemic sclerosis (scleroderma). , 1971, Annals of internal medicine.

[29]  E. Bywaters,et al.  Skeletal Muscle Involvement in Systemic Sclerosis * , 1969, Annals of the rheumatic diseases.

[30]  J. Moossy,et al.  Skeletal muscle involvement in progressive systemic sclerosis (scleroderma). , 1968, Arthritis and rheumatism.

[31]  Tuffanelli Dl.  Scleroderma and its relationship to the "collagenoses": dermatomyositis, lupus erythematosus, rheumatoid arthritis and Sjogren's syndrome. , 1962 .

[32]  R. Winkelmann,et al.  SCLERODERMA AND ITS RELATIONSHIP TO THE “COLLAGENOSES”: DERMATOMYOSITIS, LUPUS ERYTHEMATOSUS, RHEUMATOID ARTHRITIS AND SJOGREN'S SYNDROME* , 1962, The American journal of the medical sciences.

[33]  R. Winkelmann,et al.  Systemic scleroderma, A clinical study of 727 cases. , 1961, Archives of dermatology.